Drugs / FP-020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06334211 | Apr → Sep 2024 | — | Foresee Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-10-20 | Foresee Pharmaceuticals Co., Ltd. | Results Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Selective MMP-12 Inhibitor foreseepharma.com ↗
It suggests that linvemastat was well tolerated, with no Serious Adverse Events reported. |
| 2023-06-21 | Foresee Pharmaceuticals Co., Ltd. | Results Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases foreseepharma.com ↗
Inhibiting MMP-12 with FP-020 attenuated macrophage infiltration, macrophage clustering, decreased fibrotic replacement, and reduced the number of activated fibroblasts. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-20 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Selective MMP-12 Inhibitor foreseepharma.com ↗ |
| 2024-04-30 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020 foreseepharma.com ↗ |
| 2023-06-21 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases foreseepharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP-020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06334211 ↗ |
| Action | Inhibit | “MMP-12 inhibitor” NCT06334211 ↗ |
| Route | Oral | “Single and Multiple Ascending Oral Dose Study” NCT06334211 ↗ |